PLX:NYE-Protalix Biotherapeutics Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 1.25

Change

0.00 (0.00)%

Market Cap

USD 0.08B

Volume

0.29M

Analyst Target

USD 9.75
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
BHVN Biohaven Pharmaceutical Holdin..

N/A

USD 5.14B
RCUS Arcus Biosciences Inc

N/A

USD 1.58B
NUVB Nuvation Bio Inc

N/A

USD 0.74B
DNA Ginkgo Bioworks Holdings

N/A

USD 0.50B
ANRO Alto Neuroscience, Inc.

N/A

USD 0.37B
ADCT ADC Therapeutics SA

N/A

USD 0.29B
CYBN Cybin Inc

N/A

USD 0.21B
ANVS Annovis Bio Inc

N/A

USD 0.12B
ARMP Armata Pharmaceuticals Inc

N/A

USD 0.09B
OSTX OS Therapies Incorporated

N/A

USD 0.07B

ETFs Containing PLX

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 602.25% 76% C+ 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 602.25% 76% C+ 97% N/A
Trailing 12 Months  
Capital Gain 575.68% 76% C+ 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 575.68% 76% C+ 96% N/A
Trailing 5 Years  
Capital Gain 437.17% 86% B+ 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 437.17% 86% B+ 95% A
Average Annual (5 Year Horizon)  
Capital Gain 18.03% 73% C 80% B-
Dividend Return 18.03% 73% C 78% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 136.83% 36% F 6% D-
Risk Adjusted Return 13.18% 64% D 32% F
Market Capitalization 0.08B 67% D+ 25% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.